PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Immunization Programs”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,207 records · Page 67Linked to original sources
PubMed1995

A retrospective cohort study of childhood immunisation status in northern Sydney.

A survey of their children's immunisation status was conducted among mothers of babies from a three-month birth cohort (January to March 1990) in the Northern Sydney Area in 1992. Its aims were to determine the uptake of immunisation in the area, to examine factors associated with immunisation status, and to assess agreement between the parent's reporting of this status and records of councils and general practitioners. Fifty-eight per cent of the questionnaires (1004) were returned. The full immunisation rate was 86 per cent, 14 per cent were partially immunised and only four children had received no immunisations. Between 74 per cent and 82 per cent of vaccinations were on time at two, four and six months; the rate dropped to 21 per cent at 12 months. Logistic regression analysis showed that premature babies are significantly more likely to be fully immunised, whereas children who have had a serious childhood illness, those with a single mother, or whose mothers are more highly educated, are significantly less likely to be fully immunised. There was 60 per cent agreement between the parent's report of immunisation status and a subgroup of 197 council and 82 general practitioner records. Although all councils in the Northern Sydney Area have a reminder system, most immunisations were found to be done in general practices (64 per cent), where reminder systems are not common.

Child, Preschool↗
PubMed2002

[Influenza vaccine: past, present and future].

Japan has ever based its policy for controlling influenza on a strategy of vaccinating schoolchildren. Mass immunization program for schoolchildren began in 1962. The government discontinued the program in 1994, because of growing doubt about its effectiveness. However, it was recently reported that vaccinating schoolchildren against influenza provides protection and reduces mortality from influenza among elderly persons. Instead, Japanese government will begin a vaccination program for elderly persons, because the excess mortality rates increased, as the vaccination of schoolchildren was discontinued. Although vaccination rate of Japan is the lowest in developed countries at present, the supply of influenza vaccine increases double every year.

Aged↗
PubMed1970

Antibody response to various single-factor o antigens of salmonella.

The relative agglutinin responses to various single O-antigenic (Kauffmann-White) factors were measured after immunization of rabbits with several strains of heat-killed salmonella organisms. As expected, the relative strength of the responses to the various O factors was quite varied and in some cases depended on the presence or absence of other single factors. For example, antibodies to factor 12(2) were formed rapidly and to extremely high levels in rabbits immunized with either Salmonella typhi (O 9,12(1),12(2),12(3)) or S. paratyphi B (O 1,4,5,12(1),12(2)), whereas factor 12(3) in S. typhi and factor 1 in S. paratyphi B induced only minimal responses. However, rabbits immunized with S. paratyphi A var. durazzo (O 2,12(1),12(3)), which lacks factor 12(2), produced high levels of agglutinins to the 12(3) antigenic determinant. In general, most of the agglutinin responses to the various single factors measured were formed in parallel, but there were several exceptions. For instance, the responses to factors 4 and 5 were relatively strong in rabbits receiving three graded doses of S. paratyphi B. However, agglutinins to factor 4 did not appear until after the second injection, and not at all in rabbits given the full amount of antigen in one injection. In contrast, antibodies to factor 4 were formed rapidly in rabbits receiving three graded doses of a strain of S. typhimurium (O 1,4,12) lacking factor 5. Good overall agreement was obtained between agglutination and hemagglutination assays of antibodies, as demonstrated by the responses to the various O factors of S. friedenau. It was concluded that measurement of the antibody responses to the various single-factor O antigens throughout the immunization program was necessary for effective evaluation of the relative significance of these factors in antibody formation against intact bacteria.

Journal Article↗
PubMed1998

Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants.

The plethora of newly discovered vaccines implies that, in the future, many vaccines will have to be administered simultaneously to infants. We examined the potential interference with the immune response of several coadministered vaccines containing the same protein component, namely, tetanus toxoid (TT). Infants simultaneously receiving a tetravalent pneumococcal vaccine conjugated to TT (PncT) and a diphtheria-tetanus-pertussis-poliovirus-Haemophilus influenzae type b-tetanus conjugate vaccine showed significantly lower anti-H. influenzae type b polysaccharide (polyribosylribitol phosphate [PRP]) antibody concentrations than those receiving either a tetravalent pneumococcal vaccine conjugated to diphtheria toxoid or placebo. A dose range study showed that anti-PRP antibody concentrations were inversely related to the TT content of the PncT vaccines administered in infancy. Postimmunization antitetanus antibody concentrations were also affected adversely as the TT content of the coadministered vaccines was increased. This phenomenon, which we believe derives from interference by a common protein carrier, should be taken into account when the introduction of an immunization program including multiple conjugate vaccines is considered.

Antibodies, Bacterial↗
PubMed1979

Antibody response to monovalent A/New Jersey/8/76 influenza vaccine in pregnant women.

The decision to implement a mass immunization program with A/New Jersey/8/76 (Hsw1N1) influenza vaccine provided a unique opportunity to evaluate immunological responses during pregnancy. Fifty-nine pregnant and 27 nonpregnant women participated in this study. Influenza virus hemagglutination-inhhibition antibody titers were determined to A/New Jersey/8/76 (Hsw1N1), A/Japan/305/57 (H2N2), and A/Hong Kong/8/68 (H3N2) before and after a single dose of monovalent (200 chick cell agglutination units) influenza A/New Jersey/8/76 (Hsw1N1) vaccine. The difference in titers between pregnant and nonpregnant women was insignificant. Treatment of the sera with 2-mercaptoethanol disclosed a similar immunoglobulin M response to the vaccine in both groups. The mean fold rise in heterologous antibody titer was similar in pregnant and nonpregnant women. This study demonstrated that pregnant women were able to respond to an original myxovirus antigen, influenza A/New Jersey/8/76, in a manner equivalent to nonpregnant, age-matched controls.

Adolescent↗
PubMed1999

Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian authority.

The global eradication of poliomyelitis, believed to be achievable around the year 2000, relies on strategies which include high routine immunization coverage and mass vaccination campaigns, along with continuous monitoring of wild-type virus circulation by using the laboratory-based acute flaccid paralysis (AFP) surveillance. Israel and the Palestinian Authority are located in a geographical region in which poliovirus is still endemic but have been free of poliomyelitis since 1988 as a result of intensive immunization programs and mass vaccination campaigns. To monitor the wild-type virus circulation, environmental surveillance of sewage samples collected monthly from 25 to 30 sites across the country was implemented in 1989 and AFP surveillance began in 1994. The sewage samples were processed in the laboratory with a double-selective tissue culture system, which enabled economical processing of large number of samples. Between 1989 and 1997, 2,294 samples were processed, and wild-type poliovirus was isolated from 17 of them in four clusters, termed "silent outbreaks," in September 1990 (type 3), between May and September 1991 (type 1), between October 1994 and June 1995 (type 1), and in December 1996 (type 1). Fifteen of the 17 positive samples were collected in the Gaza Strip, 1 was collected in the West Bank, and 1 was collected in the Israeli city of Ashdod, located close to the Gaza Strip. The AFP surveillance system failed to detect the circulating wild-type viruses. These findings further emphasize the important role that environmental surveillance can play in monitoring the eradication of polioviruses.

Environmental Monitoring↗
PubMed2005

West Nile virus inhibits the signal transduction pathway of alpha interferon.

West Nile virus (WNV) is a human pathogen that can cause neurological disorders, including meningoencephalitis. Experiments with mice and mammalian cell cultures revealed that WNV exhibited resistance to the innate immune program induced by alpha interferon (IFN-alpha). We have investigated the nature of this inhibition and have found that WNV replication inhibited the activation of many known IFN-inducible genes, because it prevented the phosphorylation and activation of the Janus kinases JAK1 and Tyk2. As a consequence, activation of the transcription factors STAT1 and STAT2 did not occur in WNV-infected cells. Moreover, we demonstrated that the viral nonstructural proteins are responsible for this effect. Thus, our results provided an explanation for the observed resistance of WNV to IFN-alpha in cells of vertebrate origin.

Animals↗
PubMed2006

Impact of adverse publicity on MMR vaccine uptake: a population based analysis of vaccine uptake records for one million children, born 1987-2004.

AIMS: To determine the impact of adverse publicity on MMR uptake and measles susceptibility, including whether vaccination is delayed and the role of deprivation. METHODS: A population database for all Scotland containing immunisation records for over one million children (n = 1,079,327) born 1987-2004 was analysed. MMR uptake was determined by birth cohort and deprivation category. "Final" uptake (at approx age 6 years) was predicted by linear regression by birth cohort. Measles susceptibility in 1998 and 2003 was determined by postcode sector and district for cohorts combined to construct nursery and primary school age groups. RESULTS: There is evidence of a slight rise in late uptake, but insufficient to compensate for underlying declines. Late vaccination continues to be associated with deprivation, while the most affluent tend to be vaccinated promptly, or not at all. Predicted figures for "final" MMR1 uptake are over 90%, but under 95%. Measles susceptibility has increased significantly in nursery children, with an eightfold rise in the number of districts with greater than 20% susceptibility in this group (from 3 to 25). CONCLUSIONS: Increased measles susceptibility in nursery children is concerning, particularly in the most vulnerable areas. These figures are likely to increase in the future, as MMR uptake has not yet returned to the previous higher level. Increased susceptibility levels can also be expected in primary schools in the future, as levels of late uptake are insufficient to compensate. Predicted figures for "final" MMR1 uptake are under the herd immunity threshold and campaigns may be required to increase uptake among future primary school children.

Child, Preschool↗
PubMed1999

Pertussis is increasing in unimmunized infants: is a change in policy needed?

The proportion and trend in absolute number of pertussis notifications in young infants has increased each year in England and Wales since the accelerated immunization schedule was introduced. We report five infants all less than 3 months of age admitted with life threatening pertussis infection to two paediatric intensive care units. Despite aggressive cardiorespiratory support measures, three of the infants died. Pertussis remains a significant cause of morbidity and mortality in unimmunized infants. In this age group presentation is likely to be atypical and infection more severe. Public health measures to prevent the disease could be strengthened. Chemoprophylaxis should be offered to susceptible contacts and booster vaccinations against pertussis considered.

Age of Onset↗
PubMed2000

Re-vaccination of 421 children with a past history of an adverse vaccine reaction in a special immunisation service.

BACKGROUND: In Australia an adverse event following immunisation (AEFI), with the exception of anaphylaxis and encephalopathy, is no longer considered an absolute contraindication to continuing vaccination with the suspect vaccine. Despite these recommendations there is a paucity of information on the re-vaccination of such children. AIMS: To describe the re-vaccination of a large number of children with a past history of an AEFI. METHODS: A review of children attending special immunisation services in three Australian tertiary care paediatric centres. RESULTS: During the review 970 children attended of whom 469 had experienced a past AEFI. Of these, 293 had experienced minor while 176 children had experienced significant neurological or allergic reactions. The majority (421/469) were re-vaccinated, with only one child having a significant neurological event; this was transient and resolved spontaneously. CONCLUSIONS: Re-vaccination of children who have a past history of an AEFI appears safe. A special immunisation service should be part of a comprehensive immunisation programme.

Adolescent↗
PubMed2002

Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.

OBJECTIVES: To assess the cost effectiveness of a meningococcal serogroup C conjugate vaccination campaign in 0-17 year olds. DESIGN: Cost effectiveness analysis from the perspective of the healthcare provider. SETTING: England and Wales. MAIN OUTCOME MEASURE: Cost per life year saved. RESULTS: In 1998-9, immediately before the introduction of meningococcal C vaccination, the burden of serogroup C disease was considerable, with an estimated 1137 cases in people aged 0-17 years and at least 72 deaths. The vaccination campaign is estimated to have cost between 126m pound sterling ($180m, 207m) and 241 pound sterling 3m, 395m), depending on the price of the vaccine. Under base case assumptions the cost per life year saved from the vaccination campaign is estimated to be 6259 pound sterling. School based vaccination was more cost effective than general practice based vaccination because of lower delivery costs. Immunisation of infants aged under 1 year was the least cost effective component of the campaign because, although this maximises the life years gained, the three dose schedule required is more expensive than other methods of delivery. Estimates of the cost per life year saved were sensitive to assumptions on the future incidence of disease and the case fatality ratio. CONCLUSIONS: Meningococcal C vaccination is likely to be more cost effective in all age groups when the incidence of disease is high. It is also more cost effective when given to children aged 1-4 (by general practitioners) and to children and young people aged 5-17 years at school than when administered to infants under 12 months of age or young people aged 16-17 years who are not at school.

Adolescent↗
PubMed1997

Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers.

Neonates of hepatitis B surface antigen (HBsAg) positive and hepatitis B encoded antigen (HBeAg) positive mothers received 10 micrograms of recombinant hepatitis B vaccine at months 0, 1, 6, or 0, 1, 2, 12, with or without immunoglobulin at birth, and were followed up to the age of 8 years for HBsAg, anti-HBc, and anti-HBs. Some were boosted at month 60. The overall vaccine protection at month 12 was 96.2%. No child became a chronic carrier beyond the age of 3 years, showing that this vaccine provides immediate protection against HBsAg carriage, and long term protection against fetally acquired HBsAg. After month 60 hepatitis B serological markers without disease, indicating re-exposure to HBV, reappeared in comparable numbers among boosted and non-boosted children (5 for a total of 167 children). This vaccine provides long-term protection against hepatitis B chronic carriage and infection in high risk neonates with or without a month 60 booster. A booster at the age of 5-6 years or 11-12 years would reduce HBV infection, viral circulation and transmission, while ensuring long-term antibody persistence.

Carrier State↗